Inovio HIV Vaccine PENNVAX®-GP Delivered Intradermally Generated Robust, Long-Term Best-In-Class Antibody and T Cell Immune Responses
October 25, 2018 08:00 ET
|
Inovio Pharmaceuticals, Inc.
PLYMOUTH MEETING, Pa., Oct. 25, 2018 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that its synthetic HIV vaccine PENNVAX®-GP delivered via intradermal route...
Inovio Pharmaceuticals, 2018년 11월 8일 3분기 실적발표 실시
October 24, 2018 12:09 ET
|
Inovio Pharmaceuticals, Inc.
미국 펜실베이니아주 플리머스미팅, Oct. 25, 2018 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc.(NASDAQ: INO)는 2018년 11월 8일 오후 4시 30분(미국동부시간) 컨퍼런스 콜과 라이브 웹캐스트를 통해 2018년 3분기 실적을 발표한다. 프레젠테이션 음성은...
Inovio Pharmaceuticals to Report Third Quarter 2018 Financial Results on November 8, 2018
October 24, 2018 08:00 ET
|
Inovio Pharmaceuticals, Inc.
PLYMOUTH MEETING, Pa., Oct. 24, 2018 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ: INO) announced today that it will host a conference call and live webcast to report its 2018 third...
Inovio, INO-5150의 전립선암 환자 무진행 생존율 향상 및 PSA 배가 시간 지연 효과 발표
October 22, 2018 21:35 ET
|
Inovio Pharmaceuticals, Inc.
연구 결과는 유럽종양학회(ESMO)에서 발표 미국 펜실베이니아주 플리머스미팅, Oct. 23, 2018 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc.(NASDAQ: INO)는 최근 완료된 INO-5150의 임상 1b 시험 결과 전립선암 환자의 전립선특이항원 배가 시간(PSADT)이 지연되었다는 새로운 데이터를...
Inovio Presents Progression Free Survival & PSA Doubling Time Improvements in Prostate Cancer Patients Treated with INO-5150
October 22, 2018 08:00 ET
|
Inovio Pharmaceuticals, Inc.
Study Results Presented at a Major European Cancer Conference (ESMO) PLYMOUTH MEETING, Pa., Oct. 22, 2018 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that new data...
Inovio의 DNA 암호화 단일클론 항체(dMAb™) 플랫폼, 긍정적 데이터 도출과 함께 특허 및 연구비 획득
October 17, 2018 20:58 ET
|
Inovio Pharmaceuticals, Inc.
* Inovio의 dMAb 기술 새로운 미국 특허 두 건 취득 * 게이츠 재단, Inovio의 dMAb 개발 및 차세대 dMAb 전달 임상 장치에 220만 달러 지원 미국 펜실베이니아주 플리머스미팅, Oct. 18, 2018 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc.(NASDAQ: INO)가 미국...
イノビオ社によるDNAコード･モノクローナル抗体 (dMAb™) プラットフォーム、有望なデータ、特許、助成金を取得して進歩する
October 17, 2018 08:00 ET
|
Inovio Pharmaceuticals, Inc.
イノビオのdMAb技術に対し、米国で2件の特許が新発行 イノビオ、dMAb開発とdMAbデリバリー用の次世代の臨床デバイスをサポートするために、ゲイツ財団から220万ドルの助成金を取得 ペンシルベニア州プリマス･ミーティング発, Oct. 17, 2018 (GLOBE NEWSWIRE) -- イノビオ･ファーマシューティカルズ (Inovio Pharmaceuticals,...
Inovio的DNA编码单克隆抗体（dMAbTM）平台在积极数据、专利和赠款方面取得进展
October 17, 2018 08:00 ET
|
Inovio Pharmaceuticals, Inc.
Inovio的dMAb技术获两项新的美国专利 Inovio新获220万美元盖茨基金会拨款，用于开发dMAb和下一代dMAb临床交付设备 宾夕法尼亚州普利茅斯会议, Oct. 17, 2018 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc....
Inovio’s DNA-Encoded Monoclonal Antibody (dMAb™) Platform Moves Ahead with Positive Data, Patents and Grants
October 17, 2018 08:00 ET
|
Inovio Pharmaceuticals, Inc.
Two new U.S. Patents for Inovio’s dMAb technology were issued Inovio awarded new $2.2 million Gates Foundation grant to support dMAb development and next-generation dMAb delivery clinical device ...
Inovio’s Ebola Vaccine Provides 100% Protection And Elicits Long-Lasting Immune Responses in Preclinical Studies
October 15, 2018 08:00 ET
|
Inovio Pharmaceuticals, Inc.
Article in Journal of Infectious Diseases Supports RationaleFor Inovio’s Ebola Vaccine Stockpile Program PLYMOUTH MEETING, Pa., Oct. 15, 2018 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc....